Replies to post #413870 on Amarin Corp Plc (AMRN)

[lizzy241]

Tal, I assume you meant to write Mochida? Yes? In your opinion, is the in-licensing agreement between Amarin and Mochida a plus for all involved?

[ziploc_1]

Tal...Thank you for that informative post.

We have been given, long ago, the information about the 2.7 million dollars in upfront fees that Amarin paid to Mochida...This lead to our enhanced expectations of timely MND-2119 products to be marketed by Amarin....but we investors have still not been offered any information by Amarin by either its old BOD or its new BOD...about the very important issues of royalties and milestone payments due to Mochida for MND-2119 products....I assume that a BP, investing in Amarin will ask for this information and will quickly receive it....This is a glaring example, IMHO of the game being rigged against the retail investor and in favor of the institutional investor.

[ziploc_1]

Craig Granowitz was appointed chief medical officer of Amarin in Jan of 2016..He was aware of the deal between Amarin and Mochida in 2015, which provided opportunities for Amarin to work on new products containing EPA...Granowitz and Ketchum were definitely aware of MND-2119...and yet, even after the Marine patent was invaldated in 2020 allowing Generics to infringe on its CVD patent, Amarin has still done nothing to 'collaborate' with Mochida on a clearly superior, emulsified form of EPA....IMO, this alone was reason enough to necessitate the recent change in management...I hope that this policy of inaction does not persist with present management.